RESUMEN
BACKGROUND: Tegoprazan is a potassium-competitive acid blocker that inhibits gastric acid and which may be used for eradicating Helicobacter pylori. This study focuses on the pharmacokinetic interaction and safety between tegoprazan and the combination of clarithromycin, amoxicillin and bismuth in healthy Chinese subjects. METHODS: An open-label, three-period, single-center, multiple-dosage, single-sequence, phase I trial was conducted in 22 healthy subjects. In period 1, the subjects took tegoprazan 50 mg twice daily for 7 days, and in period 2 they were administered clarithromycin 500 mg, amoxicillin 1000 mg and bismuth potassium citrate 600 mg twice daily for 7 days (days 14-20). Tegoprazan, clarithromycin, amoxicillin and bismuth potassium citrate were then administered in combination for 7 days (days 21-27) in period 3. Blood samples were collected up to 12 h after the last dose of each period. Safety assessments were performed in each period. RESULTS: The geometric mean ratios (GMRs) [90% confidence interval (CI)] of maximum plasma concentration at steady state (Cmax,ss) and area under the plasma concentration-time curve over the dosing interval (AUCτ) at steady state were 195.93% (175.52-218.71%) and 287.54% (263.28-314.04%) for tegoprazan and 423.23% (382.57-468.22%) and 385.61% (354.62-419.30%) for tegoprazan metabolite M1, respectively. The GMRs (90% CI) of Cmax,ss and AUCτ were 83.69% (77.44-90.45%) and 110.30% (102.74-118.41%) for clarithromycin, 126.25% (114.73-138.93%) and 146.94% (135.33-159.55%) for 14-hydroxyclarithromycin, 75.89% (69.73-82.60%) and 94.34% (87.94-101.20%) for amoxicillin, and 158.43% (125.43-200.11%) and 183.63% (156.42-215.58%) for bismuth, respectively. All reported adverse events were mild. The frequency of adverse events during the coadministration stage was not higher than that during the single- or triple-drug administration stages. CONCLUSION: The plasma exposure of tegoprazan, M1, 14-hydroxyclarithromycin and bismuth was increased after the coadministration of tegoprazan, clarithromycin, amoxicillin and bismuth. The coadministration exhibited favorable safety and tolerability. CLINICAL TRIALS REGISTRATION: CTR20230643.
Asunto(s)
Amoxicilina , Derivados del Benceno , Bismuto , Claritromicina , Interacciones Farmacológicas , Adulto , Femenino , Humanos , Masculino , Adulto Joven , Amoxicilina/efectos adversos , Amoxicilina/farmacocinética , Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Área Bajo la Curva , Bismuto/efectos adversos , Bismuto/farmacocinética , China , Claritromicina/efectos adversos , Claritromicina/farmacocinética , Pueblos del Este de Asia , Voluntarios Sanos , Inhibidores de la Bomba de Protones/efectos adversos , Inhibidores de la Bomba de Protones/farmacocinética , Imidazoles/efectos adversos , Imidazoles/farmacocinética , Derivados del Benceno/efectos adversos , Derivados del Benceno/farmacocinéticaRESUMEN
BACKGROUND AND OBJECTIVE: Helicobacter pylori-positive ulcers are treated with a proton pump inhibitor (PPI) + two antibiotics with/without bismuth. The objective of this study was to investigate the pharmacokinetic interaction of the novel PPI anaprazole, amoxicillin and clarithromycin with/without bismuth. METHODS: This single-centre, randomised, open-label phase 1 pharmacokinetic study included healthy Chinese male participants, comprising two cohorts (cohort 1, 4 × 4 crossover design; cohort 2, 2 × 2 crossover design). In cohort 1, 24 participants received four treatment cycles with a different treatment in each cycle; the washout period between cycles was 9 days. Participants were randomly assigned to one of the following four treatment sequences (1:1:1:1): anaprazole sodium enteric-coated tablet 20 mg monotherapy, amoxicillin 1000 mg monotherapy, clarithromycin 500 mg monotherapy, and a three-drug combination (anaprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg). During each treatment cycle, study drugs were administered twice daily for four consecutive days and once in the morning on the fifth day. Cohort 2 participants were administered a single dose of the three-drug combination and a single dose of a four-drug combination (three-drug combination + bismuth 0.6 g) with a washout period of 11 ± 2 days between treatments. Blood samples were collected for pharmacokinetic analysis. RESULTS: Twenty-nine of 32 enrolled participants (cohort 1, n = 24; cohort 2, n = 8) completed the study. There were no significant differences in exposure or time to reach maximum concentration (Tmax) between each single drug or the three-drug combination (cohort 1) or between the three- and four-drug combinations (cohort 1) for any of the drugs/metabolites. CONCLUSIONS: Dose adjustments for individual drugs are not necessary with combined dosing of anaprazole, amoxicillin, clarithromycin and bismuth.
Asunto(s)
Amoxicilina , Antibacterianos , Claritromicina , Inhibidores de la Bomba de Protones , Humanos , Masculino , Amoxicilina/farmacocinética , Antibacterianos/farmacocinética , Bismuto/farmacocinética , Claritromicina/farmacocinética , Combinación de Medicamentos , Pueblos del Este de Asia , Infecciones por Helicobacter/tratamiento farmacológico , Inhibidores de la Bomba de Protones/farmacocinéticaRESUMEN
PURPOSE: Tegoprazan is a potassium-competitive acid blocker used for gastric acid suppression, which may be used with Helicobacter pylori eradication therapies. The goal of this study was to evaluate the pharmacokinetic interaction between tegoprazan and triple-antibiotic therapy containing metronidazole, tetracycline, and bismuth. METHODS: An open-label, 2-cohort, randomized, multiple-dose, crossover study was conducted in healthy subjects. In cohort 1, tegoprazan (100 mg/d) was administered orally with or without triple-antibiotic therapy (1500 mg/d metronidazole, 2000 mg/d tetracycline, and 1200 mg/d bismuth) for 7 days in each period. In cohort 2, triple-antibiotic therapy was administered orally with or without tegoprazan for 7 days in each period. Pharmacokinetic blood samples were collected within 24 h after the last dose. Safety assessments were performed. FINDINGS: Eleven cohort 1 subjects and ten cohort 2 subjects were included in the pharmacokinetic analysis. The AUCτ and Cmax at steady state geometric mean ratios (90% CIs) were 0.78 (0.73-0.83) and 0.75 (0.68-0.82) for tegoprazan; 0.77 (0.68-0.88) and 0.84 (0.72-0.98) for tegoprazan metabolite M1; 1.03 (0.98-1.08) and 1.08 (0.99-1.18) for metronidazole; 0.63 (0.56-0.70) and 0.64 (0.56-0.74) for tetracycline; and 1.55 (0.99-2.44) and 1.38 (0.72-2.66) for bismuth, respectively. All reported adverse events were mild. IMPLICATIONS: Changes in the tegoprazan, tetracycline, and bismuth pharmacokinetic parameters were detected after concurrent administration. These changes were considered mainly due to the pharmacodynamic effect of tegoprazan. The adverse events were predictable and reported as frequent adverse events during triple-antibiotic therapy. There were no significant differences in safety or tolerability between quadruple therapy, including tegoprazan and triple-antibiotic therapy. ClinicalTrials.gov identifier: NCT04066257.
Asunto(s)
Antibacterianos , Derivados del Benceno , Infecciones por Helicobacter , Helicobacter pylori , Imidazoles , Metronidazol , Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Derivados del Benceno/farmacocinética , Bismuto/farmacocinética , Bismuto/uso terapéutico , Estudios Cruzados , Quimioterapia Combinada , Voluntarios Sanos , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Imidazoles/farmacocinética , Masculino , Metronidazol/efectos adversos , Metronidazol/farmacocinética , República de Corea , Tetraciclina/efectos adversosRESUMEN
To investigate the effect of simulated weightlessness on the pharmacokinetics of orally administered moxifloxacin and the antacid Maalox or the antidiarrheal Pepto-Bismol using a tail-suspended (TS) rat model of microgravity. Fasted control and TS, jugular-vein-cannulated, male Sprague-Dawley rats received either a single 5 mg/kg intravenous dose or a single 10 mg/kg oral dose of moxifloxacin alone or with a 0.625 mL/kg oral dose of Maalox or a 1.43 mL/kg oral dose of Pepto-Bismol. Plasma concentrations of moxifloxacin were measured by HPLC. Pharmacokinetic data were analyzed using WinNonlin. Simulated weightlessness had no effect on moxifloxacin disposition after intravenous administration but significantly decreased the extent of moxifloxacin oral absorption. The coadministration of moxifloxacin with Maalox to either control or TS rats caused significant reductions in the rate and extent of moxifloxacin absorption. In contrast, the coadministration of moxifloxacin with Pepto-Bismol to TS rats had no significant effect on either the rate or the extent of moxifloxacin absorption. These interactions showed dose staggering when oral administrations of Pepto-Bismol and moxifloxacin were separated by 60 min in control rats but not in TS rats. Dose staggering was more apparent after the coadministration of Maalox and moxifloxacin in TS rats.
Asunto(s)
Antibacterianos/farmacocinética , Moxifloxacino/farmacocinética , Ingravidez/efectos adversos , Administración Oral , Hidróxido de Aluminio/farmacocinética , Animales , Antiácidos/farmacocinética , Antidiarreicos/farmacocinética , Bismuto/farmacocinética , Combinación de Medicamentos , Interacciones Farmacológicas , Hidróxido de Magnesio/farmacocinética , Masculino , Compuestos Organometálicos/farmacocinética , Ratas , Ratas Sprague-Dawley , Salicilatos/farmacocinética , Simulación de IngravidezRESUMEN
Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.
Asunto(s)
Bismuto/farmacocinética , Bismuto/toxicidad , Nanoestructuras/toxicidad , Animales , Humanos , Nanopartículas del Metal/toxicidad , Medicina de Precisión/métodos , Distribución TisularRESUMEN
BACKGROUNDS: Due to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time-consuming. METHODS: In this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent. RESULTS: The preparation method is easy and cost-effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 µM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first-order elimination kinetics and, it has a short half-life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility. CONCLUSIONS: This bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.
Asunto(s)
Bismuto , Medios de Contraste , Tomografía Computarizada por Rayos X/métodos , Animales , Bismuto/química , Bismuto/farmacocinética , Bismuto/toxicidad , Medios de Contraste/química , Medios de Contraste/farmacocinética , Medios de Contraste/toxicidad , Yohexol/química , Yohexol/farmacocinética , Riñón/diagnóstico por imagen , Riñón/metabolismo , Nanopartículas del Metal/química , Nanopartículas del Metal/toxicidad , Ratones , Ácido Pentético/química , Ácido Pentético/farmacocinética , Distribución Tisular , Imagen de Cuerpo EnteroRESUMEN
Polymersomes have the potential to be applied in targeted alpha radionuclide therapy, while in addition preventing release of recoiling daughter isotopes. In this study, we investigated the cellular uptake, post uptake processing and intracellular localization of polymersomes. Methods: High-content microscopy was used to validate polymersome uptake kinetics. Confocal (live cell) microscopy was used to elucidate the uptake mechanism and DNA damage induction. Intracellular distribution of polymersomes in 3-D was determined using super-resolution microscopy. Results: We found that altering polymersome size and concentration affects the initial uptake and overall uptake capacity; uptake efficiency and eventual plateau levels varied between cell lines; and mitotic cells show increased uptake. Intracellular polymersomes were transported along microtubules in a fast and dynamic manner. Endocytic uptake of polymersomes was evidenced through co-localization with endocytic pathway components. Finally, we show the intracellular distribution of polymersomes in 3-D and DNA damage inducing capabilities of 213Bi labeled polymersomes. Conclusion: Polymersome size and concentration affect the uptake efficiency, which also varies for different cell types. In addition, we present advanced assays to investigate uptake characteristics in detail, a necessity for optimization of nano-carriers. Moreover, by elucidating the uptake mechanism, as well as uptake extent and geometrical distribution of radiolabeled polymersomes we provide insight on how to improve polymersome design.
Asunto(s)
Portadores de Fármacos , Membranas Artificiales , Polímeros , Radioisótopos , Animales , Bismuto/química , Bismuto/farmacocinética , Línea Celular , Línea Celular Tumoral , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Endocitosis , Humanos , Ratones , Microscopía Confocal , Nanopartículas/química , Nanopartículas/metabolismo , Compuestos Orgánicos/química , Compuestos Orgánicos/farmacocinética , Polímeros/química , Polímeros/farmacocinética , Radioisótopos/química , Radioisótopos/farmacocinética , RadioterapiaRESUMEN
Selective accumulation of photosensitizers (PSs) into cancerous cells is one of the most important factors affecting photodynamic therapy (PDT) efficacy. 5-Aminolevulinic acid (5-ALA) is precursor of a strong PS, protoporphyrin-IX (Pp-IX); but it has poor permeability in lipophilic membrane of the cells due to its hydrophilic property. Therefore, establishment of an improved delivery strategy could highly affect on treatment outcome. Moreover, folate receptors (FRs) are overexpressed on the surface of many tumor cells. In the present work, targeting ligand folic acid (FA) and 5-ALA conjugated bismuth oxide nanoparticles (FA-5ALA-Bi2O3 NPs) were synthesized; and used in PDT against human nasopharyngeal carcinoma cells (KB cell line). The KB cells incubated with the synthesized NPs for 2 h; then illuminated using a custom-made red light LED lamp at the light dose of 26 J/cm2. MTT and caspase-3 activity assays were performed to evaluate the efficacy of treatment. Results showed that FR targeting ligand enables selective endocytosis of FA-5-ALA-conjugated NPs into KB cells. Improved internalization of 5-ALA into cells decreased the cell viability to about 50%, 65%, and 85% in the groups receiving FA-5ALA-Bi2O3 NPs, 5ALA-Bi2O3 NPs, free 5-ALA and subsequent PDT, respectively. Therefore, FA-5ALA-Bi2O3 NPs can significantly increase the cell killing effect of PDT.
Asunto(s)
Ácido Aminolevulínico , Bismuto , Ácido Fólico , Nanopartículas , Carcinoma Nasofaríngeo , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes , Ácido Aminolevulínico/química , Ácido Aminolevulínico/farmacocinética , Ácido Aminolevulínico/farmacología , Bismuto/química , Bismuto/farmacocinética , Bismuto/farmacología , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales , Ácido Fólico/química , Ácido Fólico/farmacocinética , Ácido Fólico/farmacología , Humanos , Nanopartículas/química , Nanopartículas/uso terapéutico , Carcinoma Nasofaríngeo/tratamiento farmacológico , Carcinoma Nasofaríngeo/metabolismo , Carcinoma Nasofaríngeo/patología , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacocinética , Fármacos Fotosensibilizantes/farmacologíaRESUMEN
Suboptimal intratumor accumulation and poorly controllable release of encapsulated drugs remain unresolved challenges hampering further advancement of nanomedicines in cancer therapy. Herein, we conceived near-infrared (NIR) laser-triggered transformable BiS@HSA/DTX multiple nanorods (mNRs), which were made of small bundles of bismuth sulfide nanorods (BiS NRs) coated with docetaxel (DTX)-inlaid human serum albumin (HSA). The BiS@HSA/DTX mNRs had a lateral size of approximately 100 nm and efficiently accumulated in the tumor microenvironment upon systemic administration in tumor-bearing nude mice. NIR laser irradiation of the tumor area caused rapid disassembly of the BiS@HSA/DTX mNRs into individual HSA-coated BiS nanorods (BiS@HSA iNRs) and triggered the release of DTX from the HSA corona, due to the local temperature increase generated by BiS NRs via the photothermal effect. The laser-induced transformation into BiS@HSA iNRs facilitated their penetration and increased the retention time in tumor. The spatiotemporal delivery behavior of the BiS@HSA/DTX mNRs could be monitored by photoacoustic/computed tomography dual-modal imaging in vivo. Furthermore, because of the excellent photothermal conversion properties of BiS NRs and laser-triggered DTX release from BiS@HSA/DTX mNRs, efficient tumor combinatorial therapy was achieved via concurrent hyperthermia and chemotherapy in mice treated with BiS@HSA/DTX mNRs upon NIR laser irradiation.
Asunto(s)
Bismuto , Docetaxel , Hipertermia Inducida , Nanotubos/química , Neoplasias Experimentales , Técnicas Fotoacústicas , Fototerapia , Sulfuros , Tomografía , Animales , Bismuto/química , Bismuto/farmacocinética , Bismuto/farmacología , Línea Celular Tumoral , Docetaxel/química , Docetaxel/farmacocinética , Docetaxel/farmacología , Femenino , Humanos , Rayos Láser , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias Experimentales/diagnóstico por imagen , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , Neoplasias Experimentales/terapia , Sulfuros/química , Sulfuros/farmacocinética , Sulfuros/farmacologíaRESUMEN
INTRODUCTION: Shotgun pellets containing bismuth (Bi) as substitute for lead (Pb) are increasingly being used due to environmental concerns. Information on toxicokinetics of Bi is lacking for the assessment of humans accidentally shot by Bi-containing shotgun alloy pellets. METHODS: Male Wistar rats were exposed to miniature alloy pellets containing Bi, tin (Sn) and minor amounts of Pb by implantation in muscle tissues of the hind legs. RESULTS: The concentrations of Bi in whole blood and urine increased up to 53 weeks after implantation. The highest concentrations of Sn in whole blood were observed three weeks after implantation, then declining to background levels 53 weeks after implantation. Lead in whole blood increased up to 13 weeks of exposure, and declined for the remaining observation period. Bismuth and Sn accumulated mainly in kidney, but also in liver, testicle and brain. Analytical field emission scanning electron microscopy of post-implant pellets showed depletion of Pb towards the pellet surface. Oxygen and chlorine accumulated in Sn rich lamellas in areas next to the pellet surface. The distribution of Bi remained visually unaffected as compared to pre-implant pellets. CONCLUSION: The concentration of Bi increased during the whole observation period in blood, urine, kidney, brain, testicle and liver. The decline in the concentrations of Pb and Sn in blood and urine after reaching the peak concentration may be related to alterations in the chemical composition and element distribution of the implanted alloy pellets.
Asunto(s)
Bismuto/farmacocinética , Contaminantes Ambientales/farmacocinética , Plomo/farmacocinética , Estaño/farmacocinética , Animales , Bismuto/sangre , Bismuto/orina , Contaminantes Ambientales/sangre , Contaminantes Ambientales/orina , Cinética , Plomo/sangre , Plomo/orina , Masculino , Microscopía Electrónica de Rastreo , Ratas , Ratas Wistar , Estaño/sangre , Estaño/orina , Distribución TisularRESUMEN
PURPOSE: PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA). In this work, we estimate the radiation dosimetry for this ligand labeled with the alpha-emitter 213Bi. METHODS: Three patients with metastatic prostate cancer underwent PET scans 0.1 h, 1 h, 2 h, 3 h, 4 h and 5 h after injection of 68Ga-PSMA-617. Source organs were kidneys, liver, spleen, salivary glands, bladder, red marrow and representative tumor lesions. The imaging nuclide 68Ga was extrapolated to the half-life of 213Bi. The residence times of 213Bi were forwarded to the instable daughter nuclides. OLINDA was used for dosimetry calculation. Results are discussed in comparison to literature data for 225Ac-PSMA-617. RESULTS: Assuming a relative biological effectiveness of 5 for alpha radiation, the dosimetry estimate revealed equivalent doses of mean 8.1 Sv RBE5/GBq for salivary glands, 8.1 Sv RBE5/GBq for kidneys and 0.52 Sv RBE5/GBq for red marrow. Liver (1.2 Sv RBE5/GBq), spleen (1.4 Sv RBE5/GBq), bladder (0.28 Sv RBE5/GBq) and other organs (0.26 SvRBE5/GBq) were not dose-limiting. The effective dose is 0.56 Sv RBE5/GBq. Tumor lesions were in the range 3.2-9.0 SvRBE5/GBq (median 7.6 SvRBE5/GBq). Kidneys would limit the cumulative treatment activity to 3.7 GBq; red marrow might limit the maximum single fraction to 2 GBq. Despite promising results, the therapeutic index was inferior compared to 225Ac-PSMA-617. CONCLUSIONS: Dosimetry of 213Bi-PSMA-617 is in a range traditionally considered reasonable for clinical application. Nevertheless, compared to 225Ac-PSMA-617, it suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSMA-617 in dose-limiting organs than the physical half-life of 213Bi, rendering this nuclide as a second choice radiolabel for targeted alpha therapy of prostate cancer.
Asunto(s)
Bismuto/administración & dosificación , Dipéptidos/administración & dosificación , Compuestos Heterocíclicos con 1 Anillo/administración & dosificación , Neoplasias de la Próstata Resistentes a la Castración/radioterapia , Radioisótopos/administración & dosificación , Radiofármacos/administración & dosificación , Efectividad Biológica Relativa , Anciano , Bismuto/farmacocinética , Bismuto/uso terapéutico , Dipéptidos/farmacocinética , Dipéptidos/uso terapéutico , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Compuestos Heterocíclicos con 1 Anillo/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Antígeno Prostático Específico , Radioisótopos/farmacocinética , Radioisótopos/uso terapéutico , Radiofármacos/farmacocinética , Radiofármacos/uso terapéutico , Distribución TisularRESUMEN
The inherent radioresistance and inaccuracy of localization of tumors weaken the clinical implementation effectiveness of radiotherapy. To overcome these limitations, hyaluronic acid-functionalized bismuth oxide nanoparticles (HA-Bi2O3 NPs) were synthesized by one-pot hydrothermal method for target-specific computed tomography (CT) imaging and radiosensitization of tumor. After functionalization with hyaluronic acid, the Bi2O3 NPs possessed favorable solubility in water and excellent biocompatibility and were uptaken specifically by cancer cells overexpressing CD44 receptors. The as-prepared HA-Bi2O3 NPs exhibited high X-ray attenuation efficiency and ideal radiosensitivity via synergizing X-rays to induce cell apoptosis and arrest the cell cycle in a dose-dependent manner in vitro. Remarkably, these properties offered excellent performance in active-targeting CT imaging and enhancement of radiosensitivity for inhibition of tumor growth. These findings demonstrated that HA-Bi2O3 NPs as theranostic agents exhibit great promise for CT imaging-guided radiotherapy in diagnosis and treatment of tumors.
Asunto(s)
Bismuto/química , Ácido Hialurónico/química , Nanopartículas/química , Radioterapia Guiada por Imagen/métodos , Tomografía Computarizada por Rayos X/métodos , Animales , Bismuto/farmacocinética , Bismuto/uso terapéutico , Línea Celular Tumoral , Medios de Contraste/química , Medios de Contraste/uso terapéutico , Femenino , Humanos , Receptores de Hialuranos/metabolismo , Ratones Endogámicos ICR , Nanopartículas/uso terapéutico , Neoplasias/diagnóstico por imagen , Neoplasias/radioterapia , Fármacos Sensibilizantes a Radiaciones/química , Fármacos Sensibilizantes a Radiaciones/farmacología , Nanomedicina Teranóstica/métodos , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: Short-term toxicological evaluations of alpha-radioimmunotherapy have been reported in preclinical assays, particularly using bismuth-213 (213Bi). Toxicity is greatly influenced not only by the pharmacokinetics and binding specificity of the vector but also by non-specific irradiation due to the circulating radiopharmaceutical in the blood. To assess this, an acute and chronic toxicity study was carried out in mice injected with 213Bi-labelled Bovine Serum Albumin (213Bi-BSA) as an example of a long-term circulating vector. METHOD: Biodistribution of 213Bi-BSA and 125I-BSA were compared in order to evaluate 213Bi uptake by healthy organs. The doses to organs for injected 213Bi-BSA were calculated. Groups of nude mice were injected with 3.7, 7.4 and 11.1 MBq of 213Bi-BSA and monitored for 385 days. Plasma parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine, were measured and blood cell counts (white blood cells, platelets and red blood cells) were performed. Mouse organs were examined histologically at different time points. RESULTS: Haematological toxicity was transient and non-limiting for all evaluated injected activities. At the highest injected activity (11.1 MBq), mice died from liver and kidney failure (median survival of 189 days). This liver toxicity was identified by an increase in both ALT and AST and by histological examination. Mice injected with 7.4 MBq of 213Bi-BSA (median survival of 324 days) had an increase in plasma BUN and creatinine due to impaired kidney function, confirmed by histological examination. Injection of 3.7 MBq of 213Bi-BSA was safe, with no plasma enzyme modifications or histological abnormalities. CONCLUSION: Haematological toxicity was not limiting in this study. Liver failure was observed at the highest injected activity (11.1 MBq), consistent with liver damage observed in human clinical trials. Intermediate injected activity (7.4 MBq) should be used with caution because of the risk of long-term toxicity to kidneys.
Asunto(s)
Bismuto/toxicidad , Albúmina Sérica Bovina/toxicidad , Animales , Bismuto/química , Bismuto/farmacocinética , Bovinos , Femenino , Ratones , Ratones Desnudos , Albúmina Sérica Bovina/química , Albúmina Sérica Bovina/farmacocinética , Distribución TisularRESUMEN
Bismuth sulphide (Bi2S3) is an excellent semiconductor and its nanoparticles have numerous significant applications including photovoltaic materials, photodiode arrays, bio-imaging, etc. Nevertheless, these nanoparticles when fabricated by chemical and physical routes tend to easily aggregate in colloidal solutions, are eco-unfriendly, cumbrous and very broad in size distribution. The aim of the present manuscript was to ecologically fabricate water dispersible, safe and stable Bi2S3 nanoparticles such that these may find use in animal imaging, diagnostics, cell labeling and other biomedical applications. Herein, we for the first time have biosynthesized highly fluorescent, natural protein capped Bi2S3 nanoparticles by subjecting the fungus Fusarium oxysporum to bismuth nitrate pentahydrate [Bi(NO3)3.5H2O] alongwith sodium sulphite (Na2SO3) as precursor salts under ambient conditions of temperature, pressure and pH. The nanoparticles were completely characterized using recognized standard techniques. These natural protein capped Bi2S3 nanoparticles are quasi-spherical in shape with an average particle size of 15 nm, maintain long term stability and show semiconductor behavior having blue shift with a band gap of 3.04 eV. Semiconductor nanocrystals are fundamentally much more fluorescent than the toxic fluorescent chemical compounds (fluorophores) which are presently largely employed in imaging, immunohistochemistry, biochemistry, etc. Biologically fabricated fluorescent nanoparticles may replace organic fluorophores and aid in rapid development of biomedical nanotechnology. Thus, biodistribution study of the so-formed Bi2S3 nanoparticles in male Sprague Dawley rats was done by radiolabelling with Technitium-99m (Tc-99m) and clearance time from blood was calculated. The nanoparticles were then employed in SPECT-CT probe for animal imaging where these imparted iodine equivalent contrast.
Asunto(s)
Bismuto/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón Único/métodos , Sulfuros/metabolismo , Animales , Bismuto/química , Bismuto/farmacocinética , Colorantes Fluorescentes/química , Colorantes Fluorescentes/metabolismo , Colorantes Fluorescentes/farmacocinética , Fusarium/metabolismo , Masculino , Nitratos/metabolismo , Puntos Cuánticos/química , Ratas Sprague-Dawley , Espectroscopía Infrarroja por Transformada de Fourier , Sulfuros/química , Sulfuros/farmacocinética , Sulfitos/metabolismo , Tecnecio/farmacocinética , Termogravimetría , Difracción de Rayos XRESUMEN
Bismuth is a heavy metal whose biogeochemical behaviour in the marine environment is poorly defined. In this study, we exposed three different species of macroalga (the chlorophyte, Ulva lactuca, the phaeophyte, Fucus vesiculosus, and the rhodophyte, Chondrus crispus) to different concentrations of Bi (up to 50 µg L(-1)) under controlled, laboratory conditions. After a period of 48-h, the phytotoxicity of Bi was measured in terms of chlorophyll fluorescence quenching, and adsorption and internalisation of Bi determined by ICP after EDTA extraction and acid digestion, respectively. For all algae, both the internalisation and total accumulation of Bi were proportional to the concentration of aqueous metal. Total accumulation followed the order: F. vesiculosus > C. crispus > U. lactuca; with respective accumulation factors of about 4200, 1700 and 600 L kg(-1). Greatest internalisation (about 33% of total accumulated Bi) was exhibited by C. crispus, the only macroalga to display a phytotoxic response in the exposures. A comparison of the present results with those reported in the literature suggests that Bi accumulation by macroalgae is significantly lower than its accumulation by marine plankton (volume concentration factors of 10(5) to 10(7)), and that the phytotoxicity of Bi is low relative to other heavy metals like Ag and Tl.
Asunto(s)
Bismuto/toxicidad , Chondrus/efectos de los fármacos , Fucus/efectos de los fármacos , Algas Marinas/efectos de los fármacos , Ulva/efectos de los fármacos , Contaminantes Químicos del Agua/toxicidad , Bismuto/farmacocinética , Clorofila/metabolismo , Chondrus/metabolismo , Fucus/metabolismo , Agua de Mar , Algas Marinas/metabolismo , Ulva/metabolismo , Contaminantes Químicos del Agua/farmacocinéticaRESUMEN
OBJECTIVE: The aim of this study was to determine the potential of different high-Z elements to act as contrast media (CMs) alongside iodine (I) in dual-CM, dual-energy (DE) computed tomography examinations. METHODS: Gadolinium (Gd), tantalum (Ta), wolfram (W), gold (Au), and bismuth (Bi) in addition to I were examined at all available kilovolt settings in a DE computed tomography scanner. Dual-energy ratios were calculated by dividing attenuation at low kilovolt by attenuation at high kilovolt. Dual-energy data sets were loaded into material decomposition software to evaluate separation of the elements from I. RESULTS: The DE ratios of Ta, W, and Au ranged between 0.9 and 1.2, being considerably lower than I at 1.9 to 2.6. These elements were completely separated from I using material decomposition. Gadolinium and Bi were more similar to I at 1.4 to 1.9. However, separation was nearly complete for Bi and suboptimal for Gd. CONCLUSIONS: Tantalum, W, and Au are ideal candidates for dual-CM examinations, whereas Bi is a slightly weaker candidate.
Asunto(s)
Medios de Contraste/farmacocinética , Aumento de la Imagen , Yodo/farmacocinética , Metales Pesados/farmacocinética , Tomografía Computarizada por Rayos X , Bismuto/farmacocinética , Gadolinio/farmacocinética , Oro/farmacocinética , Fantasmas de Imagen , Interpretación de Imagen Radiográfica Asistida por Computador , Tantalio/farmacocinética , Tungsteno/farmacocinéticaRESUMEN
BACKGROUND: To eradicate Helicobacter pylori in human pylorus and to heal duodenal ulcers, recently, a new formulation of combination tablets containing metronidazole 125 mg, tetracycline hydrochloride 125 mg and bismuth oxide 40 mg has been developed. OBJECTIVE: To investigate the pharmacokinetics of metronidazole, tetracycline and bismuth in healthy Chinese volunteers after oral administration of the test formulation. METHODS: A one-sequence, 3-period study was conducted in 12 Chinese healthy volunteers (6 male, 6 female). Volunteers each received single low dose (1 tablet) under fed condition in period 1, single high dose (3 tablets) under fasted condition in period 2, and single high dose (3 tablets) and multiple doses (3 tablets at once, 4 times daily for 7 consecutive days) under fed condition in period 3. Blood samples were collected and determined over 48 h in every period. RESULTS AND CONCLUSION: After single high dose administration under fed condition, the C max of metronidazole, tetracycline and bismuth were 6.833 ± 0.742 µg/mL, 0.8513 ± 0.1253 µg/mL and 3.32 ± 1.89 ng/mL, respectively. The C max and AUC 0-48 of metronidazole increased in proportion to the doses within the tested dose range, but tetracycline and bismuth did not. Food caused 10% and 80% decrease of the C max for metronidazole and bismuth, respectively, but did not affect tetracycline. No gender effect was found on the pharmacokinetics of the 3 ingredients. In the steady state, the C av of metronidazole, tetracycline and bismuth were 20.75 ± 3.52 µg/mL, 1.900 ± 0.243 µg/mL and 5.61 ± 1.34 ng/mL, respectively.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Bismuto/farmacocinética , Metronidazol/farmacocinética , Tetraciclina/farmacocinética , Administración Oral , Adulto , Antibacterianos/efectos adversos , Antibacterianos/sangre , Disponibilidad Biológica , Bismuto/administración & dosificación , Bismuto/efectos adversos , Bismuto/sangre , Combinación de Medicamentos , Ayuno/sangre , Femenino , Voluntarios Sanos , Humanos , Masculino , Metronidazol/administración & dosificación , Metronidazol/efectos adversos , Metronidazol/sangre , Comprimidos , Tetraciclina/administración & dosificación , Tetraciclina/efectos adversos , Tetraciclina/sangre , Adulto JovenRESUMEN
Alpha radionuclide therapy is steadily gaining importance and a large number of pre-clinical and clinical studies have been carried out. However, due to the recoil effects the daughter recoil atoms, most of which are alpha emitters as well, receive energies that are much higher than the energies of chemical bonds resulting in decoupling of the radionuclide from common targeting agents. Here, we demonstrate that polymer vesicles (i.e. polymersomes) can retain recoiling daughter nuclei based on an experimental study examining the retention of (221)Fr and (213)Bi when encapsulating (225)Ac.
Asunto(s)
Actinio/administración & dosificación , Actinio/química , Actinio/farmacocinética , Partículas alfa/uso terapéutico , Transporte Biológico Activo , Bismuto/administración & dosificación , Bismuto/química , Bismuto/farmacocinética , Butadienos/química , Composición de Medicamentos , Francio/química , Células HeLa , Humanos , Radioisótopos de Plomo/química , Método de Montecarlo , Tamaño de la Partícula , Polietileno/química , Radioisótopos/química , Radiofármacos/administración & dosificación , Radiofármacos/química , Radiofármacos/farmacocinéticaRESUMEN
Monodispersed Bi2S3-QD@SiO2-PEG nanoparticles are prepared by a one-pot method in a reverse microemulsion system, which exhibited remarkable performances in CT and fluorescence imaging in vitro and in vivo.
Asunto(s)
Bismuto/análisis , Bismuto/farmacocinética , Polietilenglicoles/análisis , Polietilenglicoles/farmacocinética , Puntos Cuánticos/análisis , Dióxido de Silicio/análisis , Dióxido de Silicio/farmacocinética , Sulfuros/análisis , Sulfuros/farmacocinética , Tomografía Computarizada por Rayos X , Animales , Línea Celular , Emulsiones/química , Ratones , Polietilenglicoles/síntesis química , Dióxido de Silicio/síntesis química , Espectrometría de Fluorescencia , Sulfuros/síntesis química , Distribución TisularRESUMEN
In recent years, bismuth has been promoted as a "green element" and is used as a substitute for the toxic lead in ammunition and other applications. However, the bioavailability and toxicity of bismuth is still not very well described. Following a hunting accident with bismuth-containing shots, a bioavailability study of bismuth from metal pellets inoculated into rat limb muscles was carried out. Bismuth could be found in urine and blood of the animals. Bio-imaging using laser ablation ICP-MS of thin sections of the tissue around the metal implant was carried out to find out more about the distribution of the metal diffusing into the tissue. Two laser ablation systems with different ablation cell designs were compared regarding their analytical performance. Low concentrations of bismuth showing a non-symmetrical pattern were detected in the tissue surrounding the metal implant. This was partly an artefact from cutting the thin sections but also bio-mobilisation of the metals of the implant could be seen. An accumulation of zinc around the implant was interpreted as a marker of inflammation. Challenges regarding sample preparation for laser ablation and bio-imaging of samples of diverse composition became apparent during the analysis.